147 related articles for article (PubMed ID: 12941126)
1. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.
Sejima T; Isoyama T; Miyagawa I
Int J Urol; 2003 Sep; 10(9):476-84. PubMed ID: 12941126
[TBL] [Abstract][Full Text] [Related]
2. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
3. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1999 Feb; 77(1):11-8. PubMed ID: 10101681
[TBL] [Abstract][Full Text] [Related]
4. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of immune escape in renal cell carcinoma].
Zheng J; Sun X; Chen J; Jiang F; Li W; Xie S
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):24-6. PubMed ID: 11977630
[TBL] [Abstract][Full Text] [Related]
6. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
7. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.
Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Oncol; 2013 Oct; 31(7):1343-9. PubMed ID: 22153754
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines.
Hara I; Hara S; Miyake H; Arakawa S; Kamidono S
Int J Oncol; 2001 Jun; 18(6):1181-5. PubMed ID: 11351249
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Fas ligand in urogenital malignant cell lines and renal cell carcinoma].
Li H; Yu L; Guo Y; Ding Y; Liu L
Zhonghua Wai Ke Za Zhi; 2000 Mar; 38(3):201-3. PubMed ID: 11832029
[TBL] [Abstract][Full Text] [Related]
11. [Expression and function of apoptosis-related genes Bcl-2/Bax and Fas/Fas L in the course of stress ulcer].
Liu J; Li ZS; Wan XJ; Wang W
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):504-9. PubMed ID: 12887767
[TBL] [Abstract][Full Text] [Related]
12. Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro.
Wang XZ; Zhang SJ; Chen YX; Chen ZX; Huang YH; Zhang LJ
World J Gastroenterol; 2004 Sep; 10(18):2706-10. PubMed ID: 15309723
[TBL] [Abstract][Full Text] [Related]
13. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo.
Koga F; Arai K; Kamai T; Abe H; Yoshida K
Anticancer Res; 2001; 21(5):3193-7. PubMed ID: 11848472
[TBL] [Abstract][Full Text] [Related]
14. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy].
Sejima T; Miyagawa I
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161
[TBL] [Abstract][Full Text] [Related]
15. β-elemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/ FasL and downregulation of Bcl-2.
Li CL; Chang L; Guo L; Zhao D; Liu HB; Wang QS; Zhang P; Du WZ; Liu X; Zhang HT; Liu Y; Zhang Y; Xie JH; Ming JG; Cui YQ; Sun Y; Zhang ZR; Jiang CL
Asian Pac J Cancer Prev; 2014; 15(23):10407-12. PubMed ID: 25556484
[TBL] [Abstract][Full Text] [Related]
16. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
17. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
18. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
[TBL] [Abstract][Full Text] [Related]
19. Fas expression in nephrectomized, non-cancerous specimens predicts post-nephrectomy chronic kidney disease progression in patients with renal and upper urinary tract malignancies.
Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Amisaki T; Takenaka A
Urol Oncol; 2013 Nov; 31(8):1812-9. PubMed ID: 22591748
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.
Biswas RS; Cha HJ; Hardwick JM; Srivastava RK
Mol Cell Biochem; 2001 Sep; 225(1-):7-20. PubMed ID: 11716366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
